A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada

Patient Characteristics and Treatment Duration of Mavacamten Obstructive HCM Patient Support Program in Canada: A Retrospective Cohort Study

This real-world study will describe the demographic and clinical characteristics and mavacamten treatment of adult patients with obstructive hypertrophic cardiomyopathy who participated in the Bristol-Myers Squibb (BMS)-sponsored CAMZYOS Patient Support Program in Canada.

Inclusion Criteria:

• Participants ≥18 years of age.
• Participants who have initiated mavacamten as part of routine clinical care, through the BMS-sponsored CAMZYOS Patient Support Program for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.
• Participants who consented to the use of their de-identified data, generated from information collected in the course of the program.

Exclusion Criteria:

• There are no exclusion criteria.